Inactivation of carbonyl reductase from human brain by phenylglyoxal and 2,3-butanedione: a comparison with aldehyde reductase and aldose reductase.
Aldehyde reductase (alcohol:NADP+ oxidoreductase, EC 1.1.1.2), aldose reductase (alditol:NAD(P)+ 1-oxidoreductase, EC 1.1.1.21) and carbonyl reductase (secondary-alcohol:NADP+ oxidoreductase, EC 1.1.1.184) constitute the enzyme family of the aldo-keto reductases, a classification based on similar physicochemical properties and substrate specificities. The present study was undertaken in order to obtain information about the structural relationships between the three enzymes. Treatment of human aldehyde and carbonyl reductase with phenylglyoxal and 2,3-butanedione caused a complete and irreversible loss of enzyme activity, the rate of loss being proportional to the concentration of the dicarbonyl reagents. The inactivation of aldehyde reductase followed pseudo-first-order kinetics, whereas carbonyl reductase showed a more complex behavior, consistent with protein modification cooperativity. NADP+ partially prevented the loss of activity of both enzymes, and an even better protection of aldehyde reductase was afforded by the combination of coenzyme and substrate. Aldose reductase was partially inactivated by phenylglyoxal, but insensitive to 2,3-butanedione. The degree of inactivation with respect to the phenylglyoxal concentration showed saturation behavior. NADP+ partially protected the enzyme at low phenylglyoxal concentrations (0.5 mM), but showed no effect at high concentrations (5 mM). These findings suggest the presence of an essential arginine residue in the substrate-binding domain of aldehyde reductase and the coenzyme-binding site of carbonyl reductase. The effect of phenylglyoxal on aldose reductase may be explained by the modification of a reactive thiol or lysine rather than an arginine residue.
D000426:Alcohol Dehydrogenase / Q000037:antagonists & inhibitors*; D000429:Alcohol Oxidoreductases / Q000037:antagonists & inhibitors*; D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000447:Aldehydes / Q000494:pharmacology*; D001120:Arginine; D001921:Brain / Q000201:enzymology*; D002074:Butanones / Q000494:pharmacology*; D003931:Diacetyl / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D008239:Lysine; D009249:NADP / Q000494:pharmacology; D010658:Phenylglyoxal / Q000494:pharmacology*; D013401:Sugar Alcohol Dehydrogenases / Q000037:antagonists & inhibitors*; D013438:Sulfhydryl Compounds
D000447:Aldehydes; D002074:Butanones; D013438:Sulfhydryl Compounds; D009249:NADP; D001120:Arginine; D000429:Alcohol Oxidoreductases; D013401:Sugar Alcohol Dehydrogenases; D000426:Alcohol Dehydrogenase; C019642:alcohol dehydrogenase (NADP+); D000449:Aldehyde Reductase; D003931:Diacetyl; D008239:Lysine; D010658:Phenylglyoxal